The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
MatsuiJ., YamamotoY., FunahashiY.E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer.2008; 122(3): 664–671.
2.
MatsuiJ., FunahashiY., UenakaT.Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res.2008; 14(17): 5458–5465.
3.
IkultaK., YanoS., TrungV.T.E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res.2009; 15(23): 7229–7239.
4.
YamadaK., YamamotoN., YamadaY.Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res.2011; 17(8): 2528–2537.
5.
BossD.S., GlenH., BeijnenJ.H.A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer.2012; 106(10): 1598–1604.
6.
NishioM., HoraiT., HoriikeA.Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br J Cancer.2013; 109(3): 538–544.
7.
ShumakerR., AluriJ., FanJ.Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers. Int J Clin Pharmacol Ther.2014; 52(4): 284–291.
8.
Lenvima [prescribing information].Woodcliff Lake, NJ: Eisai Inc; 2015.
9.
KoyamaN., SaitoK., NishiokaY.Pharmacodynamic change in plasma angiogenic proteins: A dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer.2014; 14: 530.
10.
MolinaA.M., HutsonT.E., LarkinJ.A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol.2014; 73(1): 181–189.
11.
HongD.A., AndresenC., MinkJ.A phase IB study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Proc Am Soc Clin Oncol.2012. Abstract 8594. http://meetinglibrary.asco.org/content/101118–114. Accessed March 10, 2015.
12.
MaioM., HasselJ.C., Del VecchioM.Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma. Proc Am Soc Clin Oncol.2013. Abstract 9027. http://meetinglibrary.asco.org/content/115263–132. Accessed March 10, 2015.
13.
ShermanS.I., JarzabB., CabanillasM.E.A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radio-iodine (RAI)-refractory differentiated thyroid cancer (DTC). Proc Am Soc Clin Oncol.2011. Abstract 5503. http://meetinglibrary.asco.org/content/73708-102. Accessed March 10, 2015.
14.
BallD.W., ShermanS.I., JarzabB.Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. Proc Am Soc Clin Oncol.2012. Abstract 5518. http://meetinglibrary.asco.org/content/100476–114. Accessed March 10, 2015.
15.
SchlumbergerM., JarzabB., CabanillasM.E.A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). Proc Am Soc Clin Oncol.2012. Abstract 5591. http://meetinglibrary.asco.org/content/100784–114. Accessed March 10, 2015.
16.
VergoteI., TenerielloM., PowellM.A.A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Antiopoietin-2 as a predictive marker for clinical outcomes. Proc Am Soc Clin Oncol.2013. Abstract 5520. http://meetinglibrary.asco.Org/content/l 13008–132. Accessed March 10, 2015.
17.
O'DayS., GonzalezR., KimK.A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. Proc Am Soc Clin Oncol.2013. Abstract 9026. http://meetinglibrary.asco.org/content/112958–132. Accessed March 10, 2015.
18.
SchlumbergerM., TaharaM., WirthL.J.Lenvatinib versus placebo in radio-iodine-refractory thyroid cancer. N Engl J Med.2015; 372(7): 621–630.
19.
HavelL., LeeJ.S., LeeK.H.E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or greater nonsquamous, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2014. Abstract 8043. http://meetinglibrary.asco.org/content/128475–144. Accessed March 10, 2015.
20.
MitsunagaS., IkedaM., UenoH.Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results. Proc Am Soc Clin Oncol.2013. Abstract 231. http://meetinglibrary.asco.org/content/105252–133. Accessed March 10, 2015.
21.
OkitaK., KumadaH., IkedaK.Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate. Proc Am Soc Clin Oncol.2012. Abstract 320. http://meetinglibrary.asco.org/content/187667–115. Accessed March 10, 2015.
22.
HarbourJ.W., LuoR.X., DeiS.A.Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell.1999; 98(6): 859–869.
23.
FryD.W., HarveyP.J., KellerP.R.Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Tker.2004; 3(11): 1427–1438.
24.
ToogoodP.L., HarveyP.J., RepineJ.T.Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem.2005; 48(7): 2388–2406.
25.
SchwartzG.K., LoRussoP.M., DicksonM.A.Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer.2011; 104(12): 1862–1868.
26.
FlahertyK.T., LorussoP.M., DemicheleA.Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res.2012; 18(2): 568–576.
LeonardJ.P., LaCasceA.S., SmithM.R.Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood.2012; 119(20): 4597–4607.
29.
FinnR.S., CrownJ.P., LangI.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomized phase 2 study. Lancet Oncol.2015; 16(1): 25–35.
30.
GopalanP.K., PinderM.K., ChiapporiA.A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivatedCDKN2A. Proc Am Soc Clin Oncol.2014. Abstract 8077. http://meetinglibrary.asco.org/content/135087–144. Accessed March 10, 2015.
31.
MayerE.L., GropperA.B., TungN.M.Adjuvant palociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study. Proc Am Soc Clin Oncol.2014. Abstract TPS654. http://meetinglibrary.asco.org/content/128490-144. Accessed March 10, 2015.
32.
LittmanS.J., BrusC., BurkartA.A phase II study of palociclib (PD-0332991) in adult patients with advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol GI Cancers Symposium.2015. Abstract 527. http://meetinglibrary.asco.org/content/140466–158. Accessed March 10, 2015.
33.
O'HaraM.H., EdmondsC., FarwellM.Phase II pharmacodynamics trial of palociclib in patients with KRAS mutant colorectal cancer. Proc Am Soc Clin Oncol GI Cancers Symposium.2015. Abstract 626. http://meetinglibrary.asco.org/content/133702–144. Accessed March 10, 2015.
